

Succession buzz lifts Biocon shares, but Kiran Mazumdar-Shaw says 'not imminent'
Subscribe to enjoy similar stories.Shares of Biocon rose 2.28% on Tuesday after an online report by Fortune India said founder and chairperson Kiran Mazumdar-Shaw had identified her niece, Claire Mazumdar, 37, as her successor—a disclosure investors and analysts have long awaited, given the outsized role the 73-year-old entrepreneur plays in the company she built from scratch.Within hours, however, Mazumdar-Shaw told Mint that the succession is neither decided nor imminent. "I'm not hanging up my boots any time soon," Mazumdar-Shaw said in a conversation on Tuesday evening.
"All I have said is that Claire is a worthy successor to me, but this process will take time and will follow a process."The stock's sharp move reflects how significant the question of succession has become for Biocon. Analysts have long flagged the absence of a clear heir as an overhang on the company's valuation, arguing that a business so deeply identified with a single founder carries an inherent risk premium.Biocon is India's largest biologics company—a position it holds largely because Mazumdar-Shaw persisted with the complex, capital-intensive business of biologic medicines when most large Indian pharmaceutical companies chose not to.
That tenacity built enormous value, but it also concentrated an unusual degree of institutional trust in one person.The succession question has grown louder in recent weeks as Mazumdar-Shaw has engaged more openly with the media on the subject. In an interview with the Financial Times on 10 April, Shaw said she is looking to “groom” her niece, Claire Mazumdar, founder and chief executive of Bicara Therapeutics, a US-listed biotech company.The Fortune India story, published Tuesday, said she had named Claire as her
. Read on livemint.com